PDF-Aptima HCV RNA Qualitative Assay

Aptima HCV RNA Qualitative Assay1 500237 Rev 003 Aptima For in vitro diagnostic use100 test kit General Information2I. Mark Sulkowski, MD . Professor of Medicine. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/ Hepatology. Johns Hopkins Medical Institutions. Baltimore Maryland USA. Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors. Disclosures. Introduction. SILEN-C1 trial. Virologic response. a. Methods. Baseline characteristics. Bruno Spire & Patrizia Carrieri. How to reduce HCV incidence among people who use drugs?. Increasing access to effective treatment for opioïd dependence (e.g. methadone). Diversifying harm reduction tools for safer drug consumption . Matthew Luu, Yuan Fang (Pearl) Cai, Shiming Sun, . Ziyi Cheng. PHM142 Fall . 2016. Coordinator. : Dr. Jeffrey Henderson. Instructor: Dr. David Hampson. What is Hepatitis C? . Flaviviridae. virus family. AIDS 2016 | 18-22 July 2016 | Durban, South Africa. Babikhina. . Ksenia. «. Treatment Preparedness Coalition. ». office@itpcru.org. . itpcru.org. Monitoring of drug procurement since 2010, HCV procurement since 2012. Objectives. Define elimination as it relates to infectious diseases. Understand the gaps in the current cascade of care for HCV. Identify interventions required to achieve HCV elimination in a defined population. mHCV Genotype II Key to symbols used Global Trade Item Number Manufacturer Reference Number Lot Number In Vitro Diagnostic Medical Device Internal Control Amplification Reagent Pack A Amp for Hepatitis C Virus Diagnosis: Usefulness among Chroni, LIA LAURA LEWIS-XIMENEZ PAULO SERGIO FONSECA DE SOUZA atory Noel Nutels, Rio de Janeiro, Brazil SUMMARY Background: Molecular methods are e for Diagnostics: New York State’s Experience Monica M. Parker, Ph.D. Reflexing to an HCV RNA test after a reactive antibody test is the recommended practice for laboratories 2 Several FDA - ap Chronic hepatitis C virus (HCV) infection is one of the most common chronic liver disease and accounts for 8000 to 13,000 deaths each year. . The majority of liver transplants performed in the United States are for chronic HCV. . Test. . Outcome*. Interpretation†. Further. . Actions. Nonreactive. . hepatitis. . C. . virus. . (HCV). . antibody. No HCV. . antibody . detected. No. . further. . action. . required. . Hansen Dang,. 1,2*. Yee Hui Yeo,. 1*. Satoshi Yasuda,. 3. Chung-Feng Huang,. 4. Etsuko Iio,. 5. Charles Landis,. 6. Dae Won Jun,. 7. Masaru Enomoto,. 8. Eiichi Ogawa,. 9. Pei-. Chien. Tsai,. & . Update on HCV . blood bank protocol. . Overview - . diagnostic tests. Serologic . assays: . specific antibody to hepatitis C virus (anti-HCV). Molecular . assays: HCV nucleic acid . (. nucleic. Mandatory criteria: . Probability based sampling. Basic demographic information collected (age, gender, postcode). Ethical board approval . For other criteria see SPHERE-C . protocol. Is there any recent (<10 years) evidence from testing proxy populations (e.g. pregnant women/blood donors/emergency department attendees) or from sub-populations (regional studies/older age groups) that HCV RNA prevalence in the general population could be > 1%?.